PMSNF (Proteome Sciences) Return-on-Tangible-Asset: -44.82% (As of Dec. 2025)


What is Proteome Sciences Return-on-Tangible-Asset?

Proteome Sciences PMSNF Return-on-Tangible-Asset is -44.82% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 82.71% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Proteome Sciences's annualized Net Income for the quarter that ended in Dec. 2025 was $-2.47 Mil. Proteome Sciences's average total tangible assets for the quarter that ended in Dec. 2025 was $5.50 Mil. Therefore, Proteome Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -44.82%.

The historical rank and industry rank for Proteome Sciences's Return-on-Tangible-Asset or its related term are showing as below:

PMSNF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -70.36   Med: -37.45   Max: 18.87
Current: -70.36

During the past 13 years, Proteome Sciences's highest Return-on-Tangible-Asset was 18.87%. The lowest was -70.36%. And the median was -37.45%.

PMSNF's Return-on-Tangible-Asset is ranked worse than
82.71% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.52 vs PMSNF: -70.36

Proteome Sciences  (OTCPK:PMSNF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Proteome Sciences Return-on-Tangible-Asset Related Terms


Proteome Sciences Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Proteome Sciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences Return-on-Tangible-Asset Chart

Proteome Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 18.18 -32.26 -56.12 -70.75

Proteome Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.91 -71.17 -46.97 -98.61 -44.82

PMSNF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison

For the Diagnostics & Research subindustry, Proteome Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteome Sciences Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's Return-on-Tangible-Asset falls into.



Proteome Sciences Return-on-Tangible-Asset Calculation

Proteome Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4.098/( (6.18+5.404)/ 2 )
=-4.098/5.792
=-70.75 %

Proteome Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-2.466/( (5.6+5.404)/ 2 )
=-2.466/5.502
=-44.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -44.82% mean?
Proteome Sciences (PMSNF) has a Return-on-Tangible-Asset of -44.82% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #177 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 82.7%.
Is Proteome Sciences' Return-on-Tangible-Asset too high?
Proteome Sciences' current Return-on-Tangible-Asset is -44.82%. Based on the distribution chart, Proteome Sciences ranks #177 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #177 out of 214 companies for Return-on-Tangible-Asset. This places Proteome Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current Return-on-Tangible-Asset is -44.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current Return-on-Tangible-Asset of -44.82%. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 17.5% below its estimated fair value. The current Return-on-Tangible-Asset is -44.82%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current Return-on-Tangible-Asset is -44.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proteome Sciences Business Description

Other Exchanges PRMl:UKPRM:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.